4.7 Article

Targeting non-coding RNA family members with artificial endonuclease XNAzymes

Journal

COMMUNICATIONS BIOLOGY
Volume 5, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s42003-022-03987-5

Keywords

-

Funding

  1. Wellcome Trust
  2. Royal Society through a Sir Henry Dale Fellowship [215453/Z/19/Z]
  3. Wellcome Trust [215453/Z/19/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

Non-coding RNAs (ncRNAs) offer a wealth of therapeutic targets for a range of diseases, but their secondary structures and sequence similarities pose challenges for specific knockdown. Researchers have engineered a series of artificial oligonucleotide enzymes (XNAzymes) composed of a modified nucleic acid that can specifically or preferentially cleave individual ncRNA members under physiological conditions. These XNAzymes can self-assemble into a stable nanostructure and target cancer-associated microRNAs, offering a potential platform for precise knockdown of specific non-coding RNAs with reduced off-target effects compared to other nucleic acid technologies.
Non-coding RNAs (ncRNAs) offer a wealth of therapeutic targets for a range of diseases. However, secondary structures and high similarity within sequence families make specific knockdown challenging. Here, we engineer a series of artificial oligonucleotide enzymes (XNAzymes) composed of 2'-deoxy-2'-fluoro-beta-D-arabino nucleic acid (FANA) that specifically or preferentially cleave individual ncRNA family members under quasi-physiological conditions, including members of the classic microRNA cluster miR-17 similar to 92 (oncomiR-1) and the Y RNA hY5. We demonstrate self-assembly of three anti-miR XNAzymes into a biostable catalytic XNA nanostructure, which targets the cancer-associated microRNAs miR-17, miR-20a and miR-21. Our results provide a starting point for the development of XNAzymes as a platform technology for precision knockdown of specific non-coding RNAs, with the potential to reduce off-target effects compared with other nucleic acid technologies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available